ClinicalTrialsFinder

Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Clinical Trials in Cincinnati, Ohio

1 recruitingCincinnati, Ohio

Showing 1–1 of 1 trials

Recruiting
Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812